Insecticides (India) Ltd FY26 Results & Key Updates

Revenue from operations (Standalone) ₹2,144.14 crore
Profit (Standalone) ₹135.82 crore

Reader Takeaway: Revenue growth driven by sales, but profit faced slight pressure. Management changes and ESOP aim for future stability and employee motivation.

What just happened

Insecticides (India) Limited announced its financial results for the year ended March 31, 2026. Standalone revenue from operations increased by approximately 7.09% to ₹2,144.14 crore, up from ₹2,002.26 crore in the comparable period of FY25. However, the standalone profit for the year saw a slight contraction, coming in at ₹135.82 crore compared to ₹139.77 crore in FY25.

Consolidated figures showed revenue from operations at ₹2,140.01 crore and profit at ₹139.41 crore for FY26.

Why this matters

The slight revenue growth indicates market demand for the company's products. The marginal decrease in profit, however, suggests potential pressure on margins or increased operational costs. The company also approved an Employee Stock Purchase Scheme (ESPS) 2026, which could boost employee morale and align their interests with shareholders. Management changes are also noteworthy for future strategic direction.

The backstory

Insecticides (India) Limited is a significant player in the agrochemical sector. The company has been focusing on expanding its product portfolio and market reach.

What changes now

The Board has approved the formulation of an Employee Stock Purchase Scheme 2026, which will be subject to shareholder approval at the upcoming 29th Annual General Meeting (AGM) on August 12, 2026. The scheme aims to benefit eligible employees by offering up to 2,00,000 equity shares of ₹10 face value each.

Additionally, there are changes in the management structure. Mrs. Nikunj Aggarwal has resigned as Whole Time Director, effective May 28, 2026. Mr. Sanskar Aggarwal, a member of the promoter family, has been appointed as an Additional Whole Time Director for a term of five years, effective the same date. Mr. Atul Kumar has been appointed as VP-Sales (North), a Senior Management Personnel.

Risks to watch

Investors will monitor if the slight contraction in profit is a temporary setback or a trend. The effectiveness of the new Employee Stock Purchase Scheme in motivating employees and its impact on dilution will be key. The successful integration of new management and strategic decisions will also be crucial.

Peer comparison

Insecticides (India) Ltd operates in the competitive agrochemical industry. Companies in this sector often face regulatory changes, monsoon dependency, and price volatility. While the filing doesn't provide direct peer comparison figures, the revenue growth suggests competitive positioning. Recent performance of peers like UPL, PI Industries, and Rallis India would offer broader industry context.

Context metrics (time-bound)

For the year ended March 31, 2026:

• Standalone Revenue: ₹2,144.14 crore (up 7.09% from FY25)
• Standalone Profit: ₹135.82 crore (down from FY25)
• Consolidated Revenue: ₹2,140.01 crore
• Consolidated Profit: ₹139.41 crore
• Standalone EPS: ₹46.68

What to track next

Key events to track include the 29th Annual General Meeting on August 12, 2026, where the Employee Stock Purchase Scheme will be voted upon. Future quarterly results will indicate the impact of management changes and the overall market conditions on the company's profitability and growth trajectory.